Private Equity
San Francisco-based Akkadian Ventures has closed its oversubscribed third fund at $74 million, beating its original $50 million target. Its LPs include "premier" institutional investors in the U.S. and Europe. Akkadian Ventures III focuses on secondary investing.
3 min read · 28 October 2014
Milan-based United Ventures has raised $80 million for its oversubscribed debut fund. The LPs for United Ventures One include institutions, banks and fund of funds. The fund seeks to invest in European tech startups.
3 min read · 28 October 2014
The SoftBank Group has agreed to invest $627 million in India e-commerce site Snapdeal, raising its overall total funding to over $1 billion.
1 min read · 28 October 2014
Knight Therapeutics Inc (TSX: GUD), a specialty pharmaceutical company, has committed $30 million to Teralys Capital Innovation Fund LP, a life sciences fund managed by Canadian fund of funds manager Teralys Capital. The initiative follows the company's investments in other fund vehicles, including its commitment earlier this month to Dutch venture capital firm Forbion Capital Partners. The Montréal-based Knight Therapeutics said it plans to invest up to $130 million in its fund strategy, which is intended to secure Canadian product rights for the company. Teralys manages a $600 million fund sponsored by the Caisse de dépôt et placement du Québec, Fonds de solidarité FTQ and Investissement Québec.
3 min read · 28 October 2014
Mosley Ventures has received $2 million in funding from e-mail marketing firm MailChimp. Mosley Ventures is a venture fund that focuses on early-stage tech startups in Atlanta and the Southeast.
2 min read · 28 October 2014
Q3 investing in the United States fell 27 percent. But activity levels depended a great deal on where you sat.
2 min read · 28 October 2014
Berlin-based investor Christoph Janz of Point Nine Capital, which has invested in Zendesk and more than 40 other Internet companies, says the recent IPOs of Rocket Internet and Zalando show the city can build a large company
4 min read · 28 October 2014
Watertown, Mass.-based Syros Pharmaceuticals, which focuses on treating cancer and other diseases, has raised $53 million in Series B funding.
1 min read · 27 October 2014
Ukraine situation impacts Capman; and VersoVentures in Finland targets second fund
4 min read · 27 October 2014
Corporate investors put $962 million to work in Q3, a small drop off from the $1.1 billion in previous quarter
2 min read · 25 October 2014
